Project Grant R33CA302616
Award Date 8/17/26
Completion Date 7/31/29
Dollars Obligated $432K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Cancer Institute awarded Dana-Farber Cancer Institute $643,414 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop an interleukin-21 mimic compound, designated 21H10, that enhances anti-tumor immunity in pancreatic ductal adenocarcinoma. The research centers on combining 21H10 with KRAS inhibitors to convert transient therapeutic responses into durable remissions in pancreatic cancer. The compound was developed using AI-assisted computational...
- The National Cancer Institute awarded Dana-Farber Cancer Institute $110,190 on December 27, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support research training in basic, clinical, and prevention research aligned with the National Cancer Program. The award funds investigation of mechanisms underlying neoantigen vaccine-induced epitope spreading in cancer immunotherapy. The research dissects how tumor neoantigen vaccines prime tumor-directed T cell responses and trigger...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc., $454,109 on July 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test a novel approach for reprogramming tumor-associated macrophages using theranostic nanoparticles combined with radiation therapy to stimulate the body's immune system to treat cancer. Preliminary results demonstrate that nanoparticles combined with radiation can reprogram pro-tumor macrophages into an anti-tumor phenotype...
- The National Cancer Institute, within the Department of Health and Human Services, awarded Dana-Farber Cancer Institute, Inc. $718,275 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate context-specific pathway dependencies for nuclear envelope proteins in brain cancer. The research addresses how nuclear envelope-associated proteins perform distinct biochemical functions across different cellular contexts in central nervous system cancers. The project uses an...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $134,919 under the Cancer Research Manpower program (CFDA 93.398) on June 11, 2026. The award funds structure-function and mechanistic studies of the protein-O-mannosyl transferase (POMT) complex in pediatric low-grade gliomas driven by the KIAA1549:BRAF fusion. The research aims to determine high-resolution structures of the POMT...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $606,749 on August 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate novel functions of cell cycle proteins in G1/S phase progression and cancer. The research examines the molecular roles of the cyclin B–CDK1 kinase complex in regulating cell cycle entry and DNA synthesis. Aim 1 uses mouse and human cells to identify the range of molecular functions played by cyclin B–CDK1 during G1/S phase....
- The National Cancer Institute awarded Massachusetts General Hospital $652,908 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research restoring dendritic-cell-derived immune signaling to reinvigorate T cells in glioblastoma. The project addresses the failure of immunotherapy to produce durable benefit in glioblastoma multiforme, the most aggressive primary brain tumor in adults, where standard treatments—surgery, radiation, and temozolomide—extend...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $737,086 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate CDH17 as a therapeutic target in translocation renal cell carcinoma through T cell redirection therapy. The project, titled "From Biology to Therapy: Mechanism-Informed Targeting in Translocation Renal Cell Carcinoma," addresses an unmet medical need in a rare and aggressive RCC subtype driven by TFE3 gene fusion....
- The National Cancer Institute awarded The Broad Institute, Inc., doing business as Broad Institute of MIT and Harvard, $245,297 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop chimeric molecules that trigger generation of neoantigens from proteins dysregulated in infectious disease and cancer. The molecules will be formed by joining clinical-grade protein binders with reactive groups to generate neoantigens that recruit immune system...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $230,388 on January 16, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support basic research training in cancer biology and immunotherapy. The award funds research interrogating the role of interferon gamma (IFNG) in promoting metastasis and immune evasion of triple negative breast cancer. The research comprises two aims: elucidating IFNG's role in immune evasion during triple negative breast cancer...